Wall Street analysts expect Inovio Pharmaceuticals Inc (NASDAQ:INO) to announce earnings of ($0.33) per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Inovio Pharmaceuticals’ earnings. The highest EPS estimate is ($0.32) and the lowest is ($0.33). Inovio Pharmaceuticals posted earnings of ($0.40) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 17.5%. The business is expected to announce its next earnings report on Wednesday, November 14th.
According to Zacks, analysts expect that Inovio Pharmaceuticals will report full year earnings of ($1.07) per share for the current fiscal year, with EPS estimates ranging from ($1.09) to ($1.05). For the next fiscal year, analysts expect that the firm will post earnings of ($1.16) per share, with EPS estimates ranging from ($1.25) to ($1.07). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Inovio Pharmaceuticals.
Inovio Pharmaceuticals (NASDAQ:INO) last announced its earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.22). Inovio Pharmaceuticals had a negative net margin of 252.95% and a negative return on equity of 71.53%. The business had revenue of $1.53 million during the quarter, compared to analysts’ expectations of $7.50 million. During the same period in the previous year, the company posted ($0.31) earnings per share.
In other news, CFO Peter Kies sold 35,000 shares of the firm’s stock in a transaction on Tuesday, July 10th. The shares were sold at an average price of $4.44, for a total value of $155,400.00. Following the transaction, the chief financial officer now owns 97,088 shares of the company’s stock, valued at approximately $431,070.72. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 9.40% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. MetLife Investment Advisors LLC acquired a new position in Inovio Pharmaceuticals during the 4th quarter worth $150,000. Levin Capital Strategies L.P. boosted its holdings in shares of Inovio Pharmaceuticals by 80.5% in the 2nd quarter. Levin Capital Strategies L.P. now owns 37,000 shares of the biopharmaceutical company’s stock valued at $145,000 after buying an additional 16,500 shares during the period. Emerald Advisers Inc. PA acquired a new position in shares of Inovio Pharmaceuticals in the 2nd quarter valued at about $228,000. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Inovio Pharmaceuticals by 50.2% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 101,225 shares of the biopharmaceutical company’s stock valued at $397,000 after buying an additional 33,825 shares during the period. Finally, New York State Common Retirement Fund boosted its holdings in shares of Inovio Pharmaceuticals by 14.3% in the 1st quarter. New York State Common Retirement Fund now owns 146,243 shares of the biopharmaceutical company’s stock valued at $689,000 after buying an additional 18,300 shares during the period. 32.56% of the stock is owned by institutional investors and hedge funds.
NASDAQ INO traded up $0.10 during trading hours on Friday, hitting $4.46. 416,780 shares of the stock were exchanged, compared to its average volume of 682,208. Inovio Pharmaceuticals has a 12-month low of $3.64 and a 12-month high of $7.00. The stock has a market capitalization of $398.93 million, a P/E ratio of -4.09 and a beta of 1.67.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Featured Article: What is the Book Value of a Share?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.